Zydus Cadila (Cadila Healthcare) has reported consolidated net profit of ₹391 crore for the second quarter ended September 2015, up 41 per cent from the ₹278 crore reported in the corresponding quarter last year. Total operating income stood at ₹2,460 crore, up 17 per cent from ₹2,108 crore in the corresponding quarter of the previous year on a consolidated basis, a company statement informed here. During the quarter, the company’s business in the US posted sales of ₹1,004 crore, registering 25 per cent growth. It got approval for a new product from the US FDA and two products were launched in the US market. In the domestic formulations market, it launched 13 new products, including line extensions, of which four products were the first to be launched in India.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.